PMID- 38237490
OWN - NLM
STAT- MEDLINE
DCOM- 20240214
LR  - 20240214
IS  - 1532-2653 (Electronic)
IS  - 0967-5868 (Linking)
VI  - 120
DP  - 2024 Feb
TI  - The efficacy and safety of interleukin-1 receptor antagonist in stroke patients: 
      A systematic review.
PG  - 120-128
LID - S0967-5868(24)00009-2 [pii]
LID - 10.1016/j.jocn.2024.01.009 [doi]
AB  - Stroke is the leading cause of disability worldwide, yet there is currently no 
      effective treatment available to mitigate its negative consequences. 
      Pro-inflammatory cytokines, such as interleukin-1 (IL-1), are known to play a 
      crucial role in exacerbating the aftermath of stroke. Thus, it is hypothesized 
      that blocking inflammation and administering anti-inflammatory drugs at an 
      optimal time and dosage may improve the long-term quality of life for stroke 
      patients. This systematic review examines the effectiveness and safety of IL-1 
      receptor antagonist (IL-1Ra), commercially known as "anakinra," in clinical 
      studies involving the treatment of stroke patients. A comprehensive literature 
      search was conducted until October 2023 to identify relevant studies. The search 
      yielded 1403 articles, out of which 598 were removed due to duplication. After a 
      thorough review of 805 titles and abstracts, 797 articles were further excluded, 
      resulting in 8 studies being included in this systematic review. The findings 
      from all the included studies demonstrate that IL-1Ra is safe for use in acute 
      ischemic and hemorrhagic stroke patients, with no significant adverse events 
      reported. Additionally, biomarkers, clinical assessments, serious adverse events 
      (AEs), and non-serious AEs consistently showed more favorable outcomes in IL-1Ra 
      receiving patients. Stroke elevates the levels of several inflammatory cytokines, 
      however, administration of IL-1RA directly or indirectly modulates these markers 
      and improves some clinical outcomes, suggesting a potential therapeutic benefit 
      of this intervention.
CI  - Copyright (c) 2024 Elsevier Ltd. All rights reserved.
FAU - Kazmi, Sareh
AU  - Kazmi S
AD  - Department of Neuroscience, Faculty of Advanced Medical Sciences, Tabriz 
      University of Medical Sciences, Tabriz, Iran; Neurosciences Research Center 
      (NSRC), Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, 
      Iran.
FAU - Salehi-Pourmehr, Hanieh
AU  - Salehi-Pourmehr H
AD  - Research Center for Evidence-Base Medicine, Iranian EBM Centre: A JBI Centre of 
      Excellence, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, 
      Iran; Medical Philosophy and History Research Center, Tabriz University of 
      Medical Sciences, Tabriz, Iran.
FAU - Sadigh-Eteghad, Saeed
AU  - Sadigh-Eteghad S
AD  - Neurosciences Research Center (NSRC), Aging Research Institute, Tabriz University 
      of Medical Sciences, Tabriz, Iran. Electronic address: 
      Saeed.sadigetegad@gmail.com.
FAU - Farhoudi, Mehdi
AU  - Farhoudi M
AD  - Neurosciences Research Center (NSRC), Aging Research Institute, Tabriz University 
      of Medical Sciences, Tabriz, Iran. Electronic address: Farhoudi_m@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20240118
PL  - Scotland
TA  - J Clin Neurosci
JT  - Journal of clinical neuroscience : official journal of the Neurosurgical Society 
      of Australasia
JID - 9433352
RN  - 0 (Interleukin 1 Receptor Antagonist Protein)
RN  - 0 (Cytokines)
RN  - 0 (Receptors, Interleukin-1)
SB  - IM
MH  - Humans
MH  - *Interleukin 1 Receptor Antagonist Protein/adverse effects
MH  - Quality of Life
MH  - *Stroke/drug therapy
MH  - Cytokines
MH  - Receptors, Interleukin-1/therapeutic use
OTO - NOTNLM
OT  - Anakinra
OT  - IL-1Ra
OT  - Interleukin-1 receptor antagonist
OT  - Stroke
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2024/01/19 00:42
MHDA- 2024/02/11 07:42
CRDT- 2024/01/18 18:13
PHST- 2023/09/03 00:00 [received]
PHST- 2023/11/29 00:00 [revised]
PHST- 2024/01/08 00:00 [accepted]
PHST- 2024/02/11 07:42 [medline]
PHST- 2024/01/19 00:42 [pubmed]
PHST- 2024/01/18 18:13 [entrez]
AID - S0967-5868(24)00009-2 [pii]
AID - 10.1016/j.jocn.2024.01.009 [doi]
PST - ppublish
SO  - J Clin Neurosci. 2024 Feb;120:120-128. doi: 10.1016/j.jocn.2024.01.009. Epub 2024 
      Jan 18.